Jungbäck C, Motitschke A
Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel, Paul-Ehrlich-Institut, Paul-Ehrlich Straße 51-59, 63225, Langen, Deutschland,
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014 Oct;57(10):1193-7. doi: 10.1007/s00103-014-2036-y.
The testing of immunological veterinary medicinal products (IVMPs) by official medicines control laboratories (OMCLs) is an important contribution to the control of quality, safety and efficacy of these products. Based on the legislation of the European Union (EU) and with the support of the European Directorate for the Quality of Medicines & HealthCare (EDQM) a network of OMCLs of the EU member states and Switzerland has been built. This network has established its own rules allowing the mutual recognition of test results and rapid communication of details regarding batch release or rejection. Annual reports, OMCL meetings and collaborative studies help to foster confidence between the OMCLs. The procedure for official testing is described and an overview of deficits found at testing is presented in the paper. The testing of selected batches of centrally authorized products is also performed by OMCLs and is briefly described. Communication both among OMCLs and with pharmaceutical industry is an important part of the OMCLs' work to compare test results and to optimize existing or develop new test methods. Several OMCLs are also pursuing the development of new test methods, primarily for the reduction, refinement and replacement of animal experiments in routine testing.
官方药品控制实验室(OMCLs)对免疫兽用药品(IVMPs)进行检测,这对控制这些产品的质量、安全性和有效性做出了重要贡献。基于欧盟(EU)的法规,并在欧洲药品与医疗保健质量局(EDQM)的支持下,欧盟成员国和瑞士的官方药品控制实验室网络得以建立。该网络制定了自己的规则,允许相互认可检测结果,并能迅速交流有关批次放行或拒收的详细信息。年度报告、官方药品控制实验室会议和合作研究有助于增进官方药品控制实验室之间的信任。本文描述了官方检测程序,并概述了检测中发现的不足之处。官方药品控制实验室还对部分集中授权产品的批次进行检测,并对此进行了简要描述。官方药品控制实验室之间以及与制药行业的沟通是其工作的重要组成部分,目的是比较检测结果,并优化现有检测方法或开发新的检测方法。几个官方药品控制实验室也在致力于开发新的检测方法,主要是为了在常规检测中减少、优化和替代动物实验。